Primary Open Angle Glaucoma
Conditions
Brief summary
Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay progression of glaucoma. IOP reduction has been proven to delay the onset and progression of glaucoma, and uncontrolled IOP is constantly associated with progression of visual field loss. Medical therapy is the first line in IOP reduction for Primary Open Angle Glaucoma (POAG). It is a known fact that glaucoma patients often require addition of a second antiglaucoma medications when disease progresses or tachyphylaxis occurs. It was reported that more than 50% of patients require 2 or more medications to achieve optimum IOP control. Nevertheless, compliance and adherence are often impaired with multiple-drug therapy. Combining two ocular hypotensive agents in one bottle may help patients adhere to therapeutic regimen by reducing the number of medications used and the total number of doses administered.
Interventions
Latanoprost/Timolol Fixed Combination
Sponsors
Universiti Kebangsaan Malaysia Medical Centre
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A single-center, randomized open-labeled, prospective, crossover study.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 and above 2. Able to provide informed consent 3. Diagnosed as having unilateral or bilateral, mild to moderate POAG 4. The POAG treated with only two antiglaucoma
Exclusion criteria
1. Advanced POAG 2. Patient with contraindication for topical use of a-blocker and prostaglandin analogue 3. Patient with contraindication for systemic use of a-blocker 4. Patient on systemic use of a-blocker such as metoprolol, propranolol, atenolol 5. History of orbital or ocular trauma. 6. History of cataract surgery less than 6 months. 7. History of previous ocular surgery; e.g. vitreoretinal surgery, corneal transplantation or glaucoma surgery 8. Any active eye infections or corneal ulceration. 9. Patient with ocular surface disease 10. Other ocular disease that might interfere with IOP measurements or result 11. Precious eye i.e patient with only one good eye 12. Contact lens is not allowed within 1 week before the start of study and during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy: Intraocular pressure reduction | 4 weeks | IOP reduction with LTFC given once and twice daily in POAG patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety: Side effects | 4 weeks | Side effects of LTFC given twice daily in POAG patients |
Countries
Malaysia
Contacts
Primary ContactMohd Hairul Nizam Harun, MSc
Outcome results
None listed